CA2281699A1 - Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes - Google Patents

Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes Download PDF

Info

Publication number
CA2281699A1
CA2281699A1 CA002281699A CA2281699A CA2281699A1 CA 2281699 A1 CA2281699 A1 CA 2281699A1 CA 002281699 A CA002281699 A CA 002281699A CA 2281699 A CA2281699 A CA 2281699A CA 2281699 A1 CA2281699 A1 CA 2281699A1
Authority
CA
Canada
Prior art keywords
complex
amount
micrograms
range
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002281699A
Other languages
English (en)
French (fr)
Inventor
Pramod K. Srivastava
Rajiv Y. Chandawarkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fordham University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2281699A1 publication Critical patent/CA2281699A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002281699A 1997-02-07 1998-02-03 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes Abandoned CA2281699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/796,319 1997-02-07
US08/796,319 US6017540A (en) 1997-02-07 1997-02-07 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
PCT/US1998/002193 WO1998034641A1 (en) 1997-02-07 1998-02-03 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes

Publications (1)

Publication Number Publication Date
CA2281699A1 true CA2281699A1 (en) 1998-08-13

Family

ID=25167905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002281699A Abandoned CA2281699A1 (en) 1997-02-07 1998-02-03 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes

Country Status (7)

Country Link
US (16) US6017540A (enExample)
EP (1) EP0973548A4 (enExample)
JP (1) JP2001511785A (enExample)
AU (1) AU724772B2 (enExample)
CA (1) CA2281699A1 (enExample)
WO (1) WO1998034641A1 (enExample)
ZA (1) ZA98978B (enExample)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
CA2229543A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) * 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6719974B1 (en) * 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
CA2265935C (en) 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
BE1011033A6 (fr) * 1997-03-05 1999-04-06 Univ Bruxelles Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer.
US6709672B2 (en) 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
HUP0003601A3 (en) * 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
JP2002501722A (ja) * 1997-10-31 2002-01-22 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質結合性コンジュゲートペプチド
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP1054683B1 (en) * 1998-02-20 2007-04-11 University Of Miami Modified heat shock protein-antigenic peptide complex
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1110091A1 (en) * 1998-09-04 2001-06-27 PowderJect Research Limited Immunodiagnostics using particle delivery methods
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
EP1196772A2 (en) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
GB9919733D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) * 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU1582801A (en) * 1999-11-05 2001-06-06 Board Of Regents Of The University Of Nebraska, The Methods and compositions for protection against bovine herpesvirus
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
US20010034042A1 (en) * 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
DE10019967A1 (de) * 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
WO2001091787A1 (en) 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
SK18362002A3 (sk) * 2000-06-26 2004-02-03 Stressgen Biotechnologies Corporation Použitie prostriedku s obsahom fúzneho proteínu
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
EP1322747A4 (en) * 2000-09-15 2004-12-29 Univ Connecticut Health Ct IMPROVED FORMULATIONS USING THERMAL SHOCK / STRESS PEPTIDE-PROTEIN COMPLEXES
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
KR20030074787A (ko) * 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
IL158819A0 (en) * 2001-05-31 2004-05-12 Skyepharma Inc Encapsulation of nanosuspensions in liposomes and microspheres
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
WO2003015712A2 (en) * 2001-08-20 2003-02-27 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
CA2460396A1 (en) 2001-10-01 2003-04-10 Duke University Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
KR20040105736A (ko) * 2002-02-28 2004-12-16 안티제닉스 아이엔씨 스트레스 단백질의 올리고머화에 기초한 방법 및 산물
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
RU2376029C2 (ru) * 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
AU2003234469A1 (en) * 2002-05-02 2003-11-17 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
ES2346574T3 (es) * 2002-10-02 2010-10-18 F. Hoffmann-La Roche Ag Metodo para la identificacion de peptidos antigenicos.
US20070003555A1 (en) * 2002-10-07 2007-01-04 University Of Connecticut Health Center Heat shock protein binding fragments of CD91, and uses thereof
AU2003301526A1 (en) * 2002-10-25 2004-05-13 University Of Connecticut Health Center Immunotherapy of cancer through controlled cell lysis
CA2509902A1 (en) 2002-12-13 2004-07-01 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2005062058A1 (en) * 2002-12-13 2005-07-07 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
AU2003300676A1 (en) * 2003-01-03 2004-07-29 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004066947A2 (en) * 2003-01-28 2004-08-12 Shanghai Sunway Biotech Co., Ltd. Hyperthermia oncolysis co-therapy
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
JP2006514088A (ja) * 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US7358042B2 (en) * 2003-03-14 2008-04-15 Aurelium Biopharma, Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US9701725B2 (en) * 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2525385A1 (en) * 2003-05-12 2004-11-25 The Children's Hospital Of Philadelphia Grp94-based compositions and methods of use thereof
US20060029610A1 (en) * 2003-05-12 2006-02-09 Yair Argon GRP94-based compositions and methods of use thereof
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
JPWO2006025525A1 (ja) * 2004-09-03 2008-05-08 株式会社医学生物学研究所 樹状細胞において抗原提示されやすいタンパク質の選択方法
WO2006025526A1 (ja) * 2004-09-03 2006-03-09 Medical And Biological Laboratories Co., Ltd. Ctl誘導能を獲得した樹状細胞の製造方法
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
RU2287339C1 (ru) * 2005-04-29 2006-11-20 Автономная некоммерческая организация "Институт Молекулярной Диагностики" (АНО ИнМоДи) Способ получения препарата, содержащего комплекс белков теплового шока 70,90,96, ассоциированных с антигенными пептидами
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
EP2360182A1 (en) * 2006-11-13 2011-08-24 Functional Genetics, Inc. Therapeutic targeting of escort proteins
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
EP2752193B1 (en) 2008-03-03 2017-01-11 The University of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
US7932018B2 (en) * 2008-05-06 2011-04-26 Az Electronic Materials Usa Corp. Antireflective coating composition
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
GB0816242D0 (en) * 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US20110223196A1 (en) * 2008-11-21 2011-09-15 University Of Miami Hiv/siv vaccines for the generation of mucosal and systemic immunity
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
DK2646044T3 (da) 2010-11-30 2019-11-25 Orphazyme As Metoder til at øge den intracellulære aktivitet af Hsp70
FR3005649B1 (fr) 2013-05-15 2023-03-31 Urodelia Poudre d'hydroxyapatite et son procede de production, composition a base de cette poudre et son procede de preparation et kit comprenant cette poudre
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
KR20250069686A (ko) 2014-09-15 2025-05-19 제브라 덴마크 에이/에스 아리모클로몰 제제
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
EP3423088A4 (en) * 2016-02-29 2019-11-13 The Curators Of The University Of Missouri IMMUNE-BASED CANCER THERAPY
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
MX2019008346A (es) 2017-01-13 2019-09-09 Agenus Inc Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
TWI842672B (zh) 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
SG11202001319QA (en) 2017-09-04 2020-03-30 Agenus Inc T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
FR3078887B1 (fr) 2018-03-14 2020-12-18 Urodelia Vaccins autologues contre le cancer
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
EP4221738A1 (en) * 2020-09-30 2023-08-09 Alma Bio Therapeutics Nucleic acid therapy for differential modulation of host microflora
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DE68924162T2 (de) * 1988-06-15 1996-04-25 Medical Res Council Stressproteine und verwendungen dafür.
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
DE69126668T2 (de) * 1990-11-08 1997-10-23 University College London, London Mycobacterium als adjuvans für antigene
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
CA2383007A1 (en) * 1992-03-02 1993-09-16 Chiron S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0630404A1 (en) * 1992-03-09 1994-12-28 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Protein compound capable of inhibiting tumoral growth
EP0636248A4 (en) * 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6048520A (en) * 1992-09-24 2000-04-11 Helene Curtis, Inc. Clear leave-on hair treatment composition and method
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
ES2171454T3 (es) * 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2229543A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
JPH11513369A (ja) * 1995-09-13 1999-11-16 フォーダム ユニバーシティー 熱ショックタンパク質を用いる治療及び予防方法
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
DE19602985A1 (de) * 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
CA2265935C (en) 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US5747332A (en) 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
ATE353563T1 (de) 1997-12-05 2007-03-15 Univ New Mexico Verfahren zur reinigung von hitze-schock peptidkomplexen

Also Published As

Publication number Publication date
US6387374B1 (en) 2002-05-14
US6383492B1 (en) 2002-05-07
US6017540A (en) 2000-01-25
US20030012794A1 (en) 2003-01-16
US6391306B1 (en) 2002-05-21
WO1998034641A1 (en) 1998-08-13
ZA98978B (en) 1998-08-17
US6403095B1 (en) 2002-06-11
US6436404B1 (en) 2002-08-20
US6399070B1 (en) 2002-06-04
EP0973548A1 (en) 2000-01-26
US6383493B1 (en) 2002-05-07
AU724772B2 (en) 2000-09-28
US6383494B1 (en) 2002-05-07
US6375953B1 (en) 2002-04-23
AU6145598A (en) 1998-08-26
EP0973548A4 (en) 2004-11-10
US6447780B1 (en) 2002-09-10
US6455048B1 (en) 2002-09-24
JP2001511785A (ja) 2001-08-14
US6379672B1 (en) 2002-04-30
US6399069B1 (en) 2002-06-04
US6383491B1 (en) 2002-05-07

Similar Documents

Publication Publication Date Title
US6447780B1 (en) Prevention of primary and metastatic neoplastic diseases with hsp90-peptide complexes
US5830464A (en) Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
AU703101B2 (en) Treatment or prevention of neoplastic and infectious diseases with heat shock/stress proteins
US6410028B1 (en) Therapeutic and prophylactic methods using heat shock proteins
EP0851765A1 (en) Therapeutic and prophylactic methods using heat shock proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20080204